Immunomodulatory and Anti-Inflammatory Effects of Scrophularia megalantha Ethanol Extract on an Experimental Model of Multiple Sclerosis
暂无分享,去创建一个
M. Goudarzvand | P. Saadat | A. Azadmehr | R. Hajiaghaee | Abolfazl Rahmani | H. Ebrahimi | R. Norian | Somaye Fallahnezhad | N. Miri | M. Baee | Masoud Baee
[1] A. Azadmehr,et al. Analgesic Effect and Immunomodulation Response on Pro-Inflammatory Cytokines Production by Scrophularia megalantha Extract , 2014 .
[2] A. Mirshafiey,et al. Autoantigens and autoantibodies in multiple sclerosis. , 2013, Iranian journal of allergy, asthma, and immunology.
[3] A. Afaghi,et al. Inhibition of Pro-inflammatory Cytokines by Ethyl Acetate Extract of Scrophularia striata , 2013 .
[4] M. Lopes,et al. Intracellular signaling pathways modulated by phenolic compounds: application for new anti-inflammatory drugs discovery. , 2012, Current medicinal chemistry.
[5] S. Sriram. Role of glial cells in innate immunity and their role in CNS demyelination , 2011, Journal of Neuroimmunology.
[6] F. Jadidi-Niaragh,et al. Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis , 2011, Scandinavian journal of immunology.
[7] D. Centonze,et al. T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients , 2011, PloS one.
[8] A. Afshari,et al. Evaluation of in vivo immune response activity and in vitro anti-cancer effect by Scrophularia megalantha , 2011 .
[9] M. Lynch,et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis , 2010, Brain, Behavior, and Immunity.
[10] M. Khorramizadeh,et al. Flavonoids, cinnamic acid and phenyl propanoid from aerial parts of Scrophularia striata , 2010, Pharmaceutical biology.
[11] S. Park,et al. Application of plant biotechnology in the medicinal plant, Rehmannia glutinosa Liboschitz , 2009 .
[12] A. Afshari,et al. Suppression of nitric oxide production in activated murine peritoneal macrophages in vitro and ex vivo by Scrophularia striata ethanolic extract. , 2009 .
[13] J. Russo,et al. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. , 2009, Biochimica et biophysica acta.
[14] Fu-Tong Liu,et al. Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis1 , 2009, The Journal of Immunology.
[15] Jianfei Yang,et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells , 2008, European journal of immunology.
[16] H. Link,et al. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. , 2008, Molecular immunology.
[17] P. Cabot,et al. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies , 2007, Journal of Neuroscience Methods.
[18] Yanghong Wu,et al. Glia Maturation Factor Regulation of STAT Expression: A Novel Mechanism in Experimental Autoimmune Encephalomyelitis , 2007, Neurochemical Research.
[19] G. Mosayebi,et al. C57BL/6 The Effect of Vitamin D3 on the Inhibition of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice , 2006 .
[20] B. Becher,et al. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain , 2006, Journal of Molecular Medicine.
[21] C. Teunissen,et al. Macrophages and neurodegeneration , 2005, Brain Research Reviews.
[22] E. Ongini,et al. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis , 2004, Journal of Neuroimmunology.
[23] D. Naughton,et al. Superoxide and hydrogen peroxide suppression by metal ions and their EDTA complexes. , 2004, Biochemical and biophysical research communications.
[24] Alireza Minagar,et al. Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.
[25] H. Przuntek,et al. Induction of Apoptosis of CD4+ T Cells by Immunomodulatory Therapy of Multiple Sclerosis with Glatiramer Acetate , 2003, European Neurology.
[26] R. Dai,et al. Distinct immune regulation of the response to H-2b restricted epitope of MOG causes relapsing–remitting EAE in H-2b/s mice , 2003, Journal of Neuroimmunology.
[27] Y. Saeki,et al. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35–55 induced experimental autoimmune encephalomyelitis , 1999, Journal of Neuroimmunology.
[28] O. Stuve,et al. Interferon beta in the treatment of multiple sclerosis , 1998, Neurology.
[29] Moses Rodriguez,et al. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor‐α in the central nervous system , 1997, European journal of immunology.
[30] A. Fernández,et al. Antiinflammatory effects of different extracts and harpagoside isolated from Scrophularia frutescens L. , 1996, Farmaco.
[31] M. Recio,et al. Structural Considerations on the Iridoids as Anti-Inflammatory Agents , 1994, Planta medica.
[32] H. Weiner,et al. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. , 1993, Journal of immunology.
[33] G. Kreutzberg,et al. Cytotoxicity of microglia , 1992, Journal of Neuroimmunology.
[34] S. Miller,et al. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein , 1992, Journal of Neuroimmunology.
[35] S. Waugh,et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. , 1991, Journal of immunology.
[36] E. Benveniste,et al. Induction and regulation of interleukin-6 gene expression in rat astrocytes , 1990, Journal of Neuroimmunology.
[37] H. Kirchner,et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? , 1988, Acta neurologica Scandinavica.
[38] J. Antel,et al. Pathogenesis of multiple sclerosis , 1977, European journal of clinical investigation.
[39] Bruce D. Trapp,et al. Axonal degeneration and progressive neurologic disability in multiple sclerosis , 2009, Neurotoxicity Research.
[40] Walter G. Bradley,et al. Neurology in Clinical Practice , 1997 .
[41] T. Owens,et al. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. , 2000, Journal of immunology.